Recent developments include regulatory progress in Texas, debt refinancing, and federal regulatory monitoring.

• In December 2025, Trulieve received conditional approval for a dispensing license in Texas under the Texas Compassionate Use Program, pending final regulatory approval, which would allow cultivation, manufacturing, and distribution of medical cannabis in Texas [S1].
• In December 2025, the company completed full redemption of its 8.0% Senior Secured Notes due 2026, retiring $368 million principal, and repaid its Blue Ridge Bank mortgage note totaling approximately $15.8 million [S1].
• In December 2025 and January 2026, Trulieve issued 10.5% Senior Secured Notes due 2030 in two tranches totaling approximately $200 million to fund capital expenditures and general corporate purposes [S1].
• The company continues to monitor federal regulatory developments including the potential reclassification of marijuana to Schedule III under the Controlled Substances Act, which could impact its operations and regulatory environment [S1].

Trulieve’s extensive retail network and vertical integration allow it to control product quality and customer experience, potentially supporting strong brand loyalty. Its investments in technology and data analytics may enhance operational efficiency and customer targeting. The company’s presence in multiple states with both medical and adult-use cannabis markets provides geographic diversification. Regulatory developments such as cannabis rescheduling or banking reform could reduce operational risks and costs. The company’s strong liquidity position provides financial flexibility for growth initiatives and capital expenditures.

Trulieve operates in a highly regulated industry with significant federal legal risks due to cannabis’s Schedule I status, which affects banking, financing, and operational flexibility. The company faces intense competition from local, regional, and multi-state operators, as well as illicit market participants, which could pressure pricing and market share. The company reported a net loss in the most recent fiscal year, indicating ongoing profitability challenges. Regulatory changes or delays in licensing, including in new states like Texas, could impact growth. Market and operational risks include potential changes in consumer preferences, supply chain disruptions, and legal contingencies.

Trulieve’s moat is supported by its vertically integrated operations across cultivation, manufacturing, and retail, enabling control over product quality and supply chain. Its large retail footprint and market-leading positions in key states provide scale advantages. The company’s investment in technology and customer engagement platforms supports brand loyalty and operational efficiency. Regulatory barriers and limited licensing in the cannabis industry create high entry barriers for competitors. However, the evolving regulatory landscape and increasing competition from well-capitalized multi-state operators and illicit markets present ongoing challenges to maintaining competitive advantages.

• Regulatory Risk: Federal cannabis prohibition creates legal and operational uncertainties, including risks related to banking, financing, and asset forfeiture despite state-level legalization.
• Competitive Risk: The cannabis market is highly competitive with many local and multi-state operators, which may pressure pricing, market share, and require ongoing investment in branding and operations.
• Financial Risk: The company reported net losses and faces risks related to liquidity, debt obligations, and the fair value volatility of equity method investments.
• Licensing and Expansion Risk: Delays or failures in obtaining regulatory approvals, such as the conditional license in Texas, could impact market expansion plans.
• Operational Risk: Risks include supply chain disruptions, product quality control, and reliance on key personnel and technology systems.

• Trulieve Cannabis Corp. is a vertically integrated cannabis company and multi-state operator with operations in nine U.S. states, including Florida, Arizona, Georgia, Pennsylvania, West Virginia, Ohio, Maryland, Connecticut, and Colorado [S1].
• The company is headquartered in Tallahassee, Florida, and is the largest cannabis retailer in the United States with market-leading retail operations in Arizona, Florida, Georgia, Pennsylvania, and West Virginia [S1].
• Trulieve operates through owned subsidiaries holding licenses in each state of operation [S1].
• The company’s business includes cultivation, manufacturing, and retail of cannabis products, with varying degrees of vertical integration across states; Florida and Georgia have full vertical integration, while other states have partial vertical integration [S1].
• Trulieve produces cannabis flower and a variety of cannabis products using multiple extraction techniques including supercritical ethanol, carbon dioxide, hydrocarbon extraction, and mechanical separation [S1].
• The company operates over 230 dispensaries and 15 cultivation and processing facilities as of December 31, 2025 [S1].
• Trulieve’s product portfolio includes premium, modern, and value tier brands, and it also sells partner-branded products from various cannabis brands [S1].
• The company emphasizes customer experience and engagement, with a customer-centric approach, training programs, and community outreach focused on patients, veterans, seniors, and restorative justice [S1].
• Trulieve has invested in technology and data platforms to support scaled operations, marketing, customer communication, and enterprise functions [S1].
• The company’s Subordinate Voting Shares trade on the Canadian Securities Exchange under the symbol TRUL and on the OTCQX Best Market in the U.S. under the symbol TCNNF [S1].
• As of June 30, 2026, Trulieve had cash and cash equivalents of $325.42 million, current assets of $564.83 million, and current liabilities of $95.06 million, resulting in a current ratio of 5.94 and a cash ratio of 3.42, indicating strong liquidity [S2].
• For the fiscal year ended December 31, 2025, the company reported a net loss of $116.38 million and basic and diluted EPS of -$0.58 per share [S1][S2].
• In December 2025, Trulieve received conditional approval for a dispensing license in Texas, pending final regulatory approval, which would allow cultivation, manufacturing, and distribution of medical cannabis in that state [S1].
• In December 2025, the company completed full redemption of its 8.0% Senior Secured Notes due 2026 and repaid its Blue Ridge Bank mortgage note, and issued new 10.5% Senior Secured Notes due 2030 to fund capital expenditures and general corporate purposes [S1].
• The company operates in a highly regulated and competitive cannabis market with barriers to entry due to limited licenses and regulatory requirements [S1].
• Trulieve faces competition from localized businesses, regional players, multi-state operators, and illicit market operators [S1].
• Federal cannabis law in the U.S. classifies cannabis as a Schedule I controlled substance, creating regulatory and banking challenges despite state-level legalization for medical and adult use [S1].
• The company monitors federal regulatory developments, including potential cannabis rescheduling and banking legislation, which could impact its operations and regulatory environment [S1].
• Trulieve’s financial instruments include private placement notes and fixed-rate notes, with fair value approximations disclosed [S1].
• The company has no material pending or threatened litigation as of December 31, 2025, and records contingent liabilities for probable losses related to claims [S1].
• Trulieve has consolidated variable interest entities (VIEs) in Ohio and has fully redeemed non-controlling interests in these entities, increasing ownership to 100% [S1].
• The company has related party leases and transactions disclosed in its filings [S1].
• Recent business news does not directly mention Trulieve but includes broader market and industry developments [N1][N2][N3][N4][N5][N6][N7][N8].